Centre says open to facilitate Covaxin tech transfer to ramp up production
Express News Service NEW DELHI: Amid the growing chorus for technology transfer to mass-produce Covaxin, the Centre on Thursday clarified that a sophisticated technological platform required for the process is a major constraint. This vaccine, which is an inactivated version of the Covid virus and requires the live virus to be cultured, can only be processed in laboratories categorised as biosafety level 3, stressed VK Paul, member, health, Niti Aayog, who also heads the national Covid task force. Covaxin was developed by Bharat Biotech with support from ICMR which shares the IP rights of the...
Source: newindianexpress.com